Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based study

Abstract

Outcomes for chronic myelomonocytic leukemia (CMML) are insufficiently characterized at the population level. We analyzed epidemiological trends for patients between 2001 and 2017, focusing on age, sex, race, and long-term survivors. Using the Surveillance, Epidemiology, and End Results Program, we studied 3929 patients, in four time-period (tp) cohorts, based on year of diagnosis [2001–2004 (tp1); 2005–2009 (tp2); 2010–2013 (tp3); 2014–2017 (tp4)]. Stable incidence overall, male predominance, and higher incidence for White versus Black and ‘Other’ races were noted. Three-year relative survival (RS) increased from 27.9% to 36.9% between tp1 and tp4. The most pronounced increase occurred between tp1 and tp2. All subgroups generally experienced RS improvements over time, except notably Black patients. Improvements for patients aged 85+ (3-year RS 8.4–23.6% between tp1 and tp4) and increases in long-term survivors (5-year OS from 13.2–22.3%) were observed. Additional study is warranted to explore these associations, particularly for Black patients.

Keywords:

• Chronic myelomonocytic leukemia (CMML)
• survival
• SEER
• registry
• outcomes

Authors’ contributions

Arnaud Lesegretain: conceptualization, data acquisition & analysis, methodology, writing (drafting, review & editing), visualization.

Andrew Brunner: conceptualization, writing (review and editing).

Aziz Benzohra: writing (review and editing).

Amir T. Fathi: conceptualization, writing (review & editing), visualization, supervision.

Disclosure statement

Arnaud Lesegretain is an employee of Daiichi-Sankyo Inc. and has stock and stock options of Daiichi Sankyo. Aziz Benzohra was an employee of Daiichi-Sankyo during the research and writing of this manuscript and has since left the company. Andrew Brunner reports having received consulting fees from Acceleron, Agios, BMS/Celgene, Gilead, Keros Therapeutics, Novartis, Taiho, Takeda. Amir Fathi reports having received research funding for clinical trials from Abbvie, BMS, Servier and consulting fees from Abbvie, Agios, Amgen, Astellas, Blueprint, BMS, Celgene, Daiichi Sankyo, EnClear, Forma, Genentech, Kite, Kura, Immunogen, Ipsen, Mablytics, Morphosys, Novartis, Orum, PureTech, Rige, Servier, Takeda, Pfizer, Trilium over the last 36 months.

Additional information

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.